Navigation Links
GiiResearch.com: Polycystic Ovarian Syndrome (PCOS) Therapeutics - Market to Witness Static Growth Until 2018
Date:12/1/2011

FARMINGTON, Conn., Dec. 1, 2011 /PRNewswire-iReach/ -- Global Information, Inc. presents "Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018"  by GlobalData.

(Photo:  http://photos.prnewswire.com/prnh/20111201/CG15993)

Polycystic ovarian syndrome (PCOS) is a common chronic disorder of the endocrine system in women. It mostly affects women of reproductive age (12-45 years old) and is thought to be one of the main causes of female subfertility. It is characterized by a heterogeneous appearance of anovulation, hyperandrogenemia, or secondary metabolic problems such as obesity, insulin resistance and so on.

Other names for this syndrome are polycystic ovary disease (PCOD), functional ovarian hyperandrogenism, Stein-Leventhal syndrome, ovarian hyperthecosis and sclerocystic ovary syndrome

Static growth in the PCOS Therapeutics Market in the Forecast Period

The global PCOS market was valued at $656m in 2010; GlobalData estimates the PCOS market to reach $804m by 2018 growing at a CAGR of 2.6% in the forecast period.

The rising prevalent population of co-morbid conditions such as diabetes, obesity and dyslipidemia are the key driver for the static growth in PCOS therapeutics market. The market does not have an approved drug. Treatment options include generic and off-label drugs which have lower efficacy profiles, which mean that both physician and patient satisfaction are low.

The etiology and pathology of PCOS is not clearly understood. Therefore it is difficult to identify the cause of the disease and develop a drug against it, which means that the current therapies rely on treating the symptoms rather than the disease.

The majority of participants in the PCOS therapeutics pipeline are institutions or universities. Company participation is low because most of the drugs under trial are generics and already being used for this indication, either alone or in combination. Therefore, the current pipeline products are unlikely to impact the market significantly.

Increasing Disease Population to Contribute to Market Growth

Patient population of PCOS is increasing due to a rise in co-morbid conditions such as diabetes, obesity and other cardiovascular complications. 60 million people are obese, a figure which almost doubled in the last 14 years (CDC study, Sept. 2006).

On average, 5%-10% of women suffer from PCOS. During the last decade, various programs have been created to spread awareness of the syndrome. In 2005, the American Association of Clinical Endocrinologists launched an awareness campaign to spread information regarding its complications and treatments. After this, the number of cases of self reported symptoms increased considerably.

Lack of Approved Drugs and Disease Modifiying Therapies a Barrier to PCOS Market Growth

The current PCOS therapeutics market has no specific approved products to treat the syndrome. The current drugs which are used to treat the associated condition of PCOS are generic and off-label products. Therefore the presence of generics poses a threat for the growth of the market both now and in the future. The unavailablilty of approved drug and usage of generic and off-label drugs which have low costs of therapy further reduces the revenue generated by the market.

The market mainly relies upon treating associated conditions of PCOS by using various generic and off-label products, and there is no single product which can treat all the conditions of PCOS. Current therapies are less efficacious, so patient and physician satisfaction is low. There are few companies involved in the development of molecules which can satisfy the huge unmet need of the market. There is a lack of diasease-modifying therapies for the treatment of all the conditions associated with PCOS. Most of the drugs in the clinical trials have already been used to treat this syndrome in some way or other, and these drugs lack sufficient information on safety and efficacy. This demonstrates a weak pipeline which will not encourage growth in the forecast period and acts as a barrier to market growth.

Find pharmaceutical market research, industry forecasts, and business analysis: http://www.giiresearch.com/pharmaceutical_report.shtml

About Global Information Inc.

Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

Media Contact:  Jeremy Palaia, Global Information, Inc., 1-860-674-8796, Press@gii.co.jp

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Global Information, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market
2. GiiResearch.com: Insulin Pumps - Availability of Reimbursement and Favorable Clinical Trial Data to Drive Market Growth
3. A New Target in Polycystic Kidney Disease
4. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
5. NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
6. OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment
7. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
8. Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test
9. BD and UCL Business Reach Exclusive License Agreement to Advance Development of New Diagnostic Tests for Ovarian and Breast Cancers
10. EGEN, Inc. Announces that Phase II Clinical Trial for Advanced Ovarian Cancer is Open for Enrollment
11. For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensitive Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... NEW YORK , February 23, 2017 ... more states have legalized cannabis for recreational use in 2016. ... the legal cannabis market was worth an estimated $7.2 billion ... annual growth rate of 17%. While adult recreational sales are ... billion by 2020, with a 25% CAGR. The market may ...
(Date:2/23/2017)... KNOXVILLE, Tenn. , Feb. 23, 2017 ... or the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ... Horowitz and Dominic Rodrigues as special ... and Mr. Rodrigues will advise the board on financial ... it had received an investment commitment of up to ...
(Date:2/23/2017)... Feb. 22, 2017 Orthopedic and cardiac ... as aging demographic patterns lead to an increasing ... sports- and exercise-related injuries, chronic back problems, heart ... sales gains. The future of medical implants faces ... following questions and more: - What types ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... 22, 2017 , ... Using the power of the internet, IdrisArkette.com has managed ... a period of just 24 months, thousands of individuals interested in a medical procedure ... , “The internet is not getting quieter. In fact it’s becoming noisier by the ...
(Date:2/22/2017)... ... 22, 2017 , ... ANGLESTRONG , the new recovery management app with ... App Store and Google Play . Florida-based Sober Network, Inc., the ... industry, partnered with Angle to build ANGLESTRONG. The new recovery management app is a ...
(Date:2/22/2017)... ... February 22, 2017 , ... Becker’s Spine Review, the ... featuring Michigan neurosurgeon Jay Jagannathan, M.D., as a “Spine Surgeon to Know.” ... neurosurgeons in Michigan performing minimally invasive back surgery that often results in less ...
(Date:2/22/2017)... ... ... A product of digesting a micronutrient found in soy may hold the ... foods, while others do not, a University of Pittsburgh Graduate School of Public Health-led ... by some types of “good” gut bacteria when they metabolize isoflavones (micronutrients found in ...
(Date:2/22/2017)... Staefa, Switzerland (PRWEB) , ... February 22, 2017 ... ... have difficulty hearing and 72 percent of those report that family members or ... those who think they suffer from hearing loss wear hearing aids. One reason, ...
Breaking Medicine News(10 mins):